reason report
price product lower pt
bottom line provent announc no-go decis
follow readout top-lin result moder sever ulcer
coliti uc uc peripher core thesi
maintain outperform rate prvb lower price
target per share remov model
refresh puls puls
random doubl blind placebo control trial anti-
mab patient moder sever uc primari
endpoint trial safeti toler week import
secondari endpoint includ endoscop histolog efficaci
assess well innov biopsy-bas biomark analysi
sampl obtain trial start week week latter analysi
set basi go/no-go decis investig
base target engag versu evid clinic efficaci
announc well toler biomark
power enough reprogram pathway signal patient
howev administ inhibit background therapi
insuffici clinic move needl patient permit prvb
team make unambigu no-go decis kill asset
indic discontinu program
learn part quid deal op
prvb team pull inhibitor
portfolio studi crohn diseas hypothesi
test uc base decad work toll like receptor
tlr pathway signal suggest damag cell releas
innard includ rna dna consequenti mean signal
danger request help environ rage cell death
happen seen activ uc danger signal
caus havoc across epithelium immun system potenti
lead gut permeabl immun hyperactiv epitheli
dysfunct studi prvb team ask follow
question inhibit signal moder sever uc lead
amelior danger signal lead clinic improv
 cool sens danger restor sens
chaotic environ uc gut block program
base puls signal behav either downstream
inconsequenti inflammatori pathway drive uc develop
progress outcom puls definit prvb team
abl show target engag patient pathway inhibit across
sampl without clinic benefit million dollar month
prvb team answer decad old question put anti-
adjuv therapi concept rest
sotp analysi discount
rate termin growth rate
year price history/av daili volume mil prvb
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
implic rest portfolio core thesi prvb
center around three asset manag capabl asset
drive major valu model includ teplizumab treat
type diabet treat celiac diseas
treat crohn diseas expect catalyst two
three asset year hope would show benefit
patient view long shot test reason hypothesi
manag abl get definit answer question
limit invest rapidli increas confid
engag capabl
look ahead focu remain niddk sponsor at-risk
trial patient risk develop type diabet
expect trial report top-lin result late earli
prvb next major catalyst top-lin readout phase
princ trial oral inhibitor expect
follow complet princ trial janssen option
recal would trigger payment prvb
inform catalyst click
price target lower per share lower
month price target per share remov project
revenu mileston royalti payment expens relat
updat model reflect financi
result project adjust peak revenu
prvb also liabl pay janssen development
regulatori commerci mileston singl digit royalti
commerci sale account probabl adjust basi
financi result cash runway prvb end
cash cash equival report net loss
per share versu project net loss per
share manag reiter guidanc oper cash expens
project cash runway
exclud potenti mileston payment compani elig
receiv follow conclus phase princ trial
take industri struggl whole product
close imposs imagin larg pharma compani could
produc streamlin answer quickli definit
spent mani billion dollar demonstr
best increment treatment alzheim diseas dont work costli
failur unproduct costli margin success
disappoint patient one less option treatment uc
doubt strategi capabl
compel prvb team made quick meal
import hypothesi data anim model persuas
human data support hypothesi uc best
margin definit biopsi driven studi approach allow
prvb team move focu asset human
data support inhibit signific
substanti read-through puls would
manag execut definit trial difficult space bode
well get answer take product price
time even result hope
assign provent share outperform rate price target prvb
maxim valu re-engag develop drug sidelin due
clinic failur caus poor trial design
target wrong diseas
prvb leverag partnership build ambiti portfolio focus prevent
delay autoimmun inflammatori diseas onset
experienc leadership team direct prior experi sever asset
revenu project
sum part analysi wacc calcul discount rate termin
growth rate appli
sum part analysi arriv price target per share
 cost consid part oper
asset valuat adjust probabl receiv regulatori approv base
strateg risk prvb greatest risk lie compani size rel portfolio size
decis maintain streamlin oper strategi help extend cash runway
also make execut clinic trial difficult may result failur achiev target
mileston timelin
financ risk abil rais addit fund crucial continu development
cours across compani pipelin inabl rais suffici fund need may result
program triag offload asset abil rais suffici capit may difficult
due higher need fund pipelin prvb size stage develop
licens risk call back provis relat prvb
licens agreement janssen respect factor impact
activ call back provis would valuat prvb full
impact truli account within valuat methodolog without project potenti
date and/or probabl provis activ
good sold
research develop expens
gener administr expens
sale market
profit loss oper
chang fair valu warrant liabil
total incom expens
loss oper tax
accret seri convert redeem prefer stock
net loss attribut common stockhold
good sold
research develop expens
gener administr expens
sale market
profit loss oper
chang fair valu warrant liabil
total incom expens
loss oper tax
accret seri convert redeem prefer stock
net loss attribut common stockhold
growth profit ratio
cash equival
prepaid expens current asset
properti plant equip
total liabil stockhold equiti deficit
outstand share end period thousand
select metric thousand except per share
work capit thousand
cash equival market secur
cash equival
prepaid expens current asset
properti plant equip
total liabil stockhold equiti deficit
outstand share end period thousand
select metric thousand except per share
work capit thousand
cash equival market secur
flow oper activ
reconcili net loss net cash
stock-bas consider connect acquisit product right note
chang fair valu warrant liabil
increas decreas oper asset liabil
increas inventori
increas receiv
prepaid expens current asset
net cash provid use oper activ
flow invest activ
purchas properti plant equip
net cash provid use invest activ
flow financ activ
proce initi public offer net
proce issuanc seri convert redeem prefer stock net
proce issuanc common stock
net cash provid financ activ
net increas decreas cash cash equival
cash equival begin period
cash equival end period
burn cash use opex
annual cash burn annual
year cash remain
month cash remain
flow oper activ
reconcili net loss net cash
stock-bas consider connect acquisit product right note
chang fair valu warrant liabil
increas decreas oper asset liabil
increas inventori
increas receiv
prepaid expens current asset
net cash provid use oper activ
flow invest activ
purchas properti plant equip
net cash provid use invest activ
flow financ activ
proce initi public offer net
proce issuanc seri convert redeem prefer stock net
proce issuanc common stock
net cash provid financ activ
net increas decreas cash cash equival
cash equival begin period
cash equival end period
burn cash use opex
annual cash burn annual
year cash remain
month cash remain
